| Recruiting | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma NCT06902246 | University of Miami | Phase 2 |
| Not Yet Recruiting | Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma NCT07110233 | University of California, San Francisco | N/A |
| Not Yet Recruiting | Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Loca NCT07511504 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma NCT07482059 | West China Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinom NCT07351513 | Eastern Hepatobiliary Surgery Hospital | Phase 2 |
| Recruiting | Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combinatio NCT07227012 | Pfizer | Phase 1 / Phase 2 |
| Not Yet Recruiting | Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Chec NCT07230314 | Jinling Hospital, China | Phase 2 |
| Not Yet Recruiting | A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer NCT05660213 | Fudan University | — |
| Not Yet Recruiting | HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC NCT07045558 | RenJi Hospital | — |
| Recruiting | Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma NCT06911255 | Yoon Jun Kim | Phase 1 / Phase 2 |
| Recruiting | Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere NCT06900543 | Chengdu New Radiomedicine Technology Co. LTD. | Phase 3 |
| Recruiting | SIRT Versus cTACE for Unresectable HCC (CHANCE2506) NCT06909708 | Zhongda Hospital | N/A |
| Not Yet Recruiting | Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unre NCT06896396 | Zhiyong Huang | Phase 1 / Phase 2 |
| Recruiting | The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study NCT07141056 | Guilin Medical University, China | — |
| Recruiting | TACE With Thermosensitive Nanogel Versus Embosphere for HCC NCT06593964 | Zhongda Hospital | N/A |
| Recruiting | TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma NCT06485466 | Guohui Xu | Phase 3 |
| Not Yet Recruiting | Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Fai NCT06496815 | Tongji Hospital | Phase 4 |
| Completed | A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab NCT06503250 | Hoffmann-La Roche | — |
| Recruiting | Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With NCT06280313 | Zhiyong Huang | — |
| Active Not Recruiting | A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unres NCT07065786 | Zhongda Hospital | — |
| Recruiting | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC NCT06360042 | Peking University Cancer Hospital & Institute | Phase 2 |
| Unknown | "cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma NCT06590844 | Anhui Provincial Hospital | Phase 4 |
| Recruiting | An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezoliz NCT06117891 | Bayer | — |
| Completed | Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable He NCT06315101 | Guangzhou University of Chinese Medicine | — |
| Completed | Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma NCT06310590 | Chengdu New Radiomedicine Technology Co. LTD. | Phase 1 |
| Recruiting | Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC NCT05917431 | Peking University Cancer Hospital & Institute | Phase 2 |
| Completed | Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study NCT05667064 | AstraZeneca | — |
| Unknown | Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma NCT05957640 | Zhongda Hospital | Phase 1 |
| Recruiting | Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Ca NCT06788353 | Sun Yat-sen University | — |
| Not Yet Recruiting | Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thromb NCT05286320 | National Taiwan University Hospital | Phase 1 / Phase 2 |
| Terminated | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezoliz NCT05199285 | Academic and Community Cancer Research United | Phase 2 |
| Withdrawn | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally A NCT05327738 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC NCT05096715 | Massachusetts General Hospital | Phase 1 |
| Not Yet Recruiting | Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma NCT05507632 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Recruiting | Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, NCT05168163 | Academic and Community Cancer Research United | Phase 2 |
| Recruiting | Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant NCT05103904 | Emory University | Phase 2 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Unknown | A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepato NCT05214339 | Sun Yat-sen University | Phase 2 |
| Unknown | DEB-TACE+HAIC vs. HAIC for Large HCC NCT05263219 | Second Affiliated Hospital of Guangzhou Medical University | Phase 3 |
| Completed | 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer NCT05176223 | Mayo Clinic | Phase 2 |
| Unknown | HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure NCT05135364 | Yue Han | Phase 2 |
| Unknown | Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma NCT04947956 | Shanghai Zhongshan Hospital | — |
| Active Not Recruiting | Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver NCT04605731 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresec NCT04736121 | Sirtex Medical | N/A |
| Active Not Recruiting | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Ca NCT04770896 | Hoffmann-La Roche | Phase 3 |
| Active Not Recruiting | A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma NCT04829383 | Howard S Hochster | Phase 2 |
| Unknown | Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma NCT04605185 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 |
| Unknown | HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC NCT05582278 | Wen Li | Phase 2 |
| Active Not Recruiting | Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (I NCT07204327 | Zhongda Hospital | — |
| Completed | Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hep NCT04401800 | BeiGene | Phase 2 |
| Unknown | SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT NCT04387695 | First Affiliated Hospital of Zhejiang University | Phase 3 |
| Active Not Recruiting | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver NCT04175912 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) NCT03896646 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inh NCT03942328 | Mayo Clinic | Phase 1 / Phase 2 |
| Recruiting | Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereo NCT07305428 | The University of Hong Kong | N/A |
| Active Not Recruiting | Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer NCT07298538 | Tianjin Medical University Cancer Institute and Hospital | — |
| Terminated | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer NCT03695250 | Edward Kim | Phase 1 / Phase 2 |
| Withdrawn | A Clinical Study of Precision TACE (P-TACE) With Surefire NCT03345225 | University of Miami | N/A |
| Active Not Recruiting | Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer NCT03186898 | NRG Oncology | Phase 3 |
| Active Not Recruiting | Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cell NCT03107416 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma NCT02989870 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With NCT02006030 | Polaris Group | Phase 2 |
| Completed | TACE Study-Liver Embolization Perfusion (VGH Radiology LIU) NCT02093104 | University of British Columbia | — |
| Completed | Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be R NCT01900002 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer NCT01556490 | Boston Scientific Corporation | N/A |
| Unknown | Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib NCT01217034 | Kindai University | Phase 2 |
| Completed | Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma NCT01176604 | M.D. Anderson Cancer Center | N/A |
| Completed | Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Met NCT01015833 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Rem NCT01004978 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior System NCT00988741 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Phase 2 |
| Completed | Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma NCT00829465 | Eastern Hepatobiliary Surgery Hospital | Phase 4 |
| Completed | An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer NCT00247676 | Pfizer | Phase 2 |
| Approved For Marketing | Himalaya Early Access Program NCT05345678 | AstraZeneca | — |